QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF For Our Patients Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Licata, A. A Search for Related Content PubMed PubMed Citation Articles by Licata, A. A

AMBULATORY CARE

Discovery, Clinical Development, and Therapeutic Uses of Bisphosphonates

Consultant, Metabolic Bone Center; Research Director, Department of Endocrinology, The Cleveland Clinic Foundation, 1063 Kirtland Ln., Lakewood, OH 44107-1423, fax 216/445-1656, LICATAA{at}ccf.org

Reprints: Dr. Licata

OBJECTIVE: To review the literature concerning the history, development, and therapeutic uses of bisphosphonates.

DATA SOURCES: English-language articles were identified through a search of MEDLINE (through December 2004) using the key word bisphosphonate. Reference lists of pivotal studies, reviews, and full prescribing information for the approved agents were also examined.

STUDY SELECTION AND DATA EXTRACTION: Selected studies included those that discussed the discovery and initial applications of bisphosphonates, as well as their historical development, pharmacokinetic and pharmacodynamic properties, and current therapeutic uses.

DATA SYNTHESIS: Bisphosphonates structurally resemble pyrophosphates (naturally occurring polyphosphates) and have demonstrated similar physicochemical effects to pyrophosphates. In addition, bisphosphonates reduce bone turnover and resist hydrolysis when administered orally. The information gained from initial work with etidronate generated a considerable scientific effort to design new and more effective bisphosphonates. The PCP moiety in the general bisphosphonate structure is essential for binding to hydroxyapatite and allows for a number of chemical variations by changing the 2 lateral side chains (designated R¹ and R²). The R¹ side chain determines binding affinity to hydroxyapatite, and the R² side chain determines antiresorptive potency. Accordingly, each bisphosphonate has its own characteristic profile of activity.

CONCLUSIONS: The bisphosphonates reduce bone turnover, increase bone mass, and decrease fracture risk and therefore have a significant place in the management of skeletal disorders including osteoporosis, Paget's disease, bone metastases, osteogenesis imperfecta, and heterotopic ossification.

Key Words: bisphosphonates, osteoporosis, Paget's disease

Published Online, March 8, 2005. www.theannals.com, DOI 10.1345/aph.1E357

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-05-012-H01

This article has been cited by other articles:

				P. A. Sanjideh, P. E. Rossouw, P. M. Campbell, L. A. Opperman, and P. H. Buschang Tooth movements in foxhounds after one or two alveolar corticotomies Eur J Orthod, February 1, 2010; 32(1): 106 - 113. [Abstract] [Full Text] [PDF]

				J. L. Shaker Paget's disease of bone: a review of epidemiology, pathophysiology and management Therapeutic Advances in Musculoskeletal Diseases, December 1, 2009; 1(2): 107 - 125. [Abstract] [PDF]

				A. Mariotti Bisphosphonates and Osteonecrosis of the Jaws J Dent Educ., August 1, 2008; 72(8): 919 - 929. [Abstract] [Full Text] [PDF]

				A. Dudakovic, A. J. Wiemer, K. M. Lamb, L. A. Vonnahme, S. E. Dietz, and R. J. Hohl Inhibition of Geranylgeranyl Diphosphate Synthase Induces Apoptosis through Multiple Mechanisms and Displays Synergy with Inhibition of Other Isoprenoid Biosynthetic Enzymes J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1028 - 1036. [Abstract] [Full Text] [PDF]

				E. J. MacLaughlin and C. L. Raehl ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults Am. J. Health Syst. Pharm., February 15, 2008; 65(4): 343 - 357. [Full Text] [PDF]

				S. B. Goodman, W. Jiranek, E. Petrow, and A. W. Yasko The Effects of Medications on Bone J. Am. Acad. Ortho. Surg., August 1, 2007; 15(8): 450 - 460. [Abstract] [Full Text] [PDF]

				M. C. Adornato, I. Morcos, and J. Rozanski The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors J Am Dent Assoc, July 1, 2007; 138(7): 971 - 977. [Abstract] [Full Text] [PDF]

				M. P. Whyte Paget's Disease of Bone N. Engl. J. Med., August 10, 2006; 355(6): 593 - 600. [Full Text] [PDF]

				J.-T. Woo, M. Kawatani, M. Kato, T. Shinki, T. Yonezawa, N. Kanoh, H. Nakagawa, M. Takami, K. H. Lee, P. H. Stern, et al. Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts PNAS, March 21, 2006; 103(12): 4729 - 4734. [Abstract] [Full Text] [PDF]

				A. Badros, D. Weikel, A. Salama, O. Goloubeva, A. Schneider, A. Rapoport, R. Fenton, N. Gahres, E. Sausville, R. Ord, et al. Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors J. Clin. Oncol., February 20, 2006; 24(6): 945 - 952. [Abstract] [Full Text] [PDF]

				C. A. MIGLIORATI, J. CASIGLIA, J. EPSTEIN, P. L. JACOBSEN, M. A. SIEGEL, and S.-B. WOO Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper J Am Dent Assoc, December 1, 2005; 136(12): 1658 - 1668. [Abstract] [Full Text] [PDF]